Eliem exits stealth with $80M to run midphase pain trials, advance pipeline of neuro programs

Eliem Therapeutics has exited stealth with $80 million and plans to treat chronic pain, depression, epilepsy and anxiety. The Anglo-American startup will use the money to advance a pipeline led by a palmitoylethanolamide (PEA) prodrug for the treatment of chronic pain.